Borstkanker Onderzoek Groep
23
2
11
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
13.0%
3 terminated/withdrawn out of 23 trials
50.0%
-36.5% vs industry average
26%
6 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Management of Low-risk (Grade I and II) DCIS
Role: collaborator
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Role: collaborator
Postoperative Re-irradiaTion With and Without HYPERthermia: Toxicity, Quality of Life and Survival in Patients With Locoregional Recurrent Breast Cancer
Role: collaborator
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Role: lead
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Role: lead
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
Role: lead
Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study
Role: lead
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)
Role: lead
Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy
Role: collaborator
DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy
Role: collaborator
Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects
Role: collaborator
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Role: collaborator
Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer
Role: collaborator
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Role: collaborator
Effectiveness of Personalized Surveillance and Aftercare for Breast Cancer
Role: collaborator
Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast
Role: collaborator
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
Role: lead
Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer
Role: lead
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
Role: lead
DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer
Role: collaborator